Chugai Pharmaceutical Co Ltd 2023 IR
The report highlights Chugai Pharmaceutical's progress in its TOP I 2030 growth strategy during the fiscal year 2023. Key achievements include steady progress in R&D with 95 projects in the pipeline, the full operation of the Chugai Life Science Park Yokohama, and the establishment of a corporate venture capital firm in Boston. Financially, the company achieved revenue exceeding 1 trillion yen for the second consecutive year, driven by strong overseas sales of Hemlibra and Alecensa. On the sustainability front, Chugai achieved a 100% sustainable electricity ratio across its domestic sites and made progress toward its Mid-Term Environmental Goals 2030.
Company: Chugai Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2023
Type: IR
Pages: 98
Chugai Pharmaceutical Co Ltd
Annual Report
The report highlights Chugai Pharmaceutical's progress in its TOP I 2030 growth strategy during the fiscal year 2023. Key achievements include steady progress in R&D with 95 projects in the pipeline, the full operation of the Chugai Life Science Park Yokohama, and the establishment of a corporate venture capital firm in Boston. Financially, the company achieved revenue exceeding 1 trillion yen for the second consecutive year, driven by strong overseas sales of Hemlibra and Alecensa. On the sustainability front, Chugai achieved a 100% sustainable electricity ratio across its domestic sites and made progress toward its Mid-Term Environmental Goals 2030.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Renewable Energy
Women in Management
Net Zero Target
Employees